Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (324)	8/11/2003 8:13:03 PM
From: Miljenko Zuanic	Read Replies (1) of 824

Ian, <<And we still have Pex reducing deaths without introducing adverse side effects. Personally I have a hard time believing that the FDA will say,>> We do not know does (and how much) Pexe reduce death rate. Only that MI-death combination is at significance (at 30%). They mentioned few secondary endpoints positive as well (prospective one of them is 30 days mortality, non-MI and MI related), but again no specific which ones. Also Bell mentioned (at CC) that even 1%-tage point reduction in mortality is medical important. Is it? To be honest, I do not give SHIT about their AHA presentation, IF I can not have real-time poster reprint and discussion section on Web. IMCL presented Erbitux data (in 2001) at ASCO, at the nose of the MDs and analysts, still NONE show any concern about data and NDA file. ONLY, Miljenko Zuanic, pointed (9 months early) that they have two subgroup pts population (irino-refractory and irino-stable), still data are presented without separating this two groups and no survival benefit for any of them. So, be careful, is my simplest massage to you. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next